A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection

Clinical Infectious Diseases

Volumn 40, Issue 4, 2005, Pages 594-600

  Cardiello, Peter G ^a,b,e   Hassink, Elly ^a,b   Ananworanich, Jintanat ^a   Srasuebkul, Preeyaporn ^a   Samor, Tarika ^a   Mahanontharit, Apicha ^a   Ruxrungtham, Kiat ^a   Hirschel, Bernard ^c   Lange, Joep ^b   Phanuphak, Praphan ^a   Cooper, David A ^d  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; ITRACONAZOLE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE PSYCHOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STRUCTURED TREATMENT INTERRUPTION; TREATMENT FAILURE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 13944262121     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427695     Document Type: Article

References (7)

1. Yeni PG, Hammer SM, Carpenter CC MA, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288:222-35.
2. Dybul M, Chun TW, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A 2001; 98:15161-6.
3. Kroon ED, Ungsedhapand C, Ruxrungtham K, et al. A randomized, double blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). AIDS 2000; 14:1349-56.
4. Cardiello P, van Heeswijk RP, Hassink E, et al. Simplifying protease inhibitor therapy with once daily dosing of saquinavir soft gelatin capsules/ritonavir (1,600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr 2002; 29:464-70.
5. Johnson VA, Brun-Vezinet F, Clotet B. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11:215-21.
6. Ananworanich J, Nuesch R, Le Braz M, et al. Swiss HIV Cohort Study. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-7.
7. Dybul M, Nies-Kraske E, Robin Dewar R, et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of HIV infection. J Infect Dis 2004; 189:1974-82.